#One key iqvia license
The agreement also includes a right of first refusal for an exclusive license for Breezula®, a phase III ready asset (clascoterone 7.5% solution) to treat alopecia in Greater China.ĭiana Harbort, President of Cosmo’s Dermatology Division, said: “We are very pleased to partner with 3SBio. Cosmo will receive an upfront payment of US$ 6.5 million, potential development and sales milestones totaling up to US$ 63.5 million and customary ascending high single digit or double-digit royalties on net sales. Cosmo will be the exclusive supplier of the API for the term of the agreement and for the finished product for the initial commercialization period until such time as manufacturing has been transferred to 3SBio for sale in Greater China. Under the terms of the License agreement, 3SBio will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to develop and commercialize Winlevi® in Greater China. Androgen receptor inhibitors represented by Winlevi® are very likely to provide a new treatment for billions of Chinese acne patients, showing huge market potential in Greater China. However, acne treatment rate remains at very low level, and there lacks effective treatment. Data from Frost & Sullivan’s market report shows that more than 100 million young people aging from 10 to 25 years old suffered from acne in China in 2018. Among them, the proportion of patients suffering from acne scars ranges from 3% to 7%, causing physical and psychological damage to the patients. According to “2019 China Acne Treatment Guidance”, over 95% of Chinese are suffering from acne in various degrees. The major product classes predominantly used to treat acne have been available for nearly 40 years.
#One key iqvia skin
According to the prescriptions generated, Winlevi® has been one of the most successful US launches in the topical acne space in the last 15 years.Īcne, a chronic inflammatory skin disease, is one of the most common reasons patients visit a dermatologist. About 10,000 US physicians have prescribed Winlevi® to date. Winlevi® was launched in the US in November 2021 by Sun Pharma and is already the most prescribed branded topical acne drug in the US based on IQVIA data. It is the first in class topical androgen receptor inhibitor that tackles the androgen hormone component of acne and is the first new mechanism of action in acne approved by the FDA in 40 years.
Winlevi® has been approved by the United States Food & Drug Administration (FDA) as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older.
(SIX: COPN, XETRA: C43) (“Cosmo”) and 3SBio (1530.HK) today announced the signing of a License Agreement for Winlevi® (clascoterone) cream 1% in Mainland China, Taiwan, Hong Kong and Macao (“Greater China”). 53 LRĭublin, Ireland & Shenyang, China – 28 July 2022: Cosmo Pharmaceuticals N.V.
0 kommentar(er)
